Pricing

Acer Therapeutics Inc (ACER)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Christopher Schelling
Employees:
40
ONE GATEWAY CENTER (300 WASHINGTON ST.), SUITE 356, NEWTON, MA, 02458
(844) 902-6100
    Formally known as:
  • Opexa Therapeutics, Inc.
Stock Split History
DateRatio
2004-04-14 1:50
2006-06-19 1:1
2012-12-17 1:4
2015-09-29 1:8
2017-09-21 96:1000
Acer Therapeutics focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available